Kenneth Brian Gordon, MD

Publications

• Sequencing of Targeted Therapy in Psoriasis: Does it Matter?

  (Boswell ND, Singla S, Gordon KB.) Am J Clin Dermatol. 2024 Sep;25(5):795-810 PMID: 39003351 SCOPUS ID: 2-s2.0-85198405473 07/14/2024

• Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.

  (Armstrong AW, Augustin M, Beaumont JL, Pham TP, Hudgens S, Gordon KB, Zhuo J, Becker B, Zhong Y, Kisa RM, Banerjee S, Papp KA.) Dermatol Ther (Heidelb). 2024 Aug;14(8):2235-2248 PMID: 39080153 PMCID: PMC11333388 SCOPUS ID: 2-s2.0-85200024132 07/31/2024

• Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).

  (Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D.) J Eur Acad Dermatol Venereol. 2024 Aug;38(8):1543-1554 PMID: 38451052 SCOPUS ID: 2-s2.0-85187120510 03/07/2024

• Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.

  (Blauvelt A, Gordon KB, Langley RG, Branigan PJ, Chen Y, Miller M, Han C, Fakharzadeh S, Muñoz-Elías EJ, Armstrong AW.) J Invest Dermatol. 2024 Jun 25 PMID: 38936766 SCOPUS ID: 2-s2.0-85199086852 06/28/2024

• Bimekizumab for the treatment of psoriasis.

  (Thapar M, Patel M, Gordon K.) Immunotherapy. 2024 Apr;16(7):431-446 PMID: 38506262 SCOPUS ID: 2-s2.0-85188760913 03/20/2024

• Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.

  (Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, de Cuyper D, Davies O, Thaçi D.) Br J Dermatol. 2024 Mar 15;190(4):477-485 PMID: 37950894 SCOPUS ID: 2-s2.0-85187961316 11/11/2023

• The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.

  (Burshtein J, Shah M, Zakria D, Lockshin B, Crowley J, Merola JF, Gordon K, Shahriari M, Korman NJ, Chovatiya R, Kalb R, Lebwohl M.) Dermatol Ther (Heidelb). 2024 Feb;14(2):323-339 PMID: 38340237 PMCID: PMC10891030 02/10/2024

• Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.

  (Papp KA, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont JL, Pham TP, Kisa R, Napoli AA, Banerjee S, Armstrong AW.) JAMA Dermatol. 2024 Feb 01;160(2):204-209 PMID: 38117487 PMCID: PMC10733845 SCOPUS ID: 2-s2.0-85180996904 12/20/2023

• Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil™ 2 study

  (Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG.) Future Rare Diseases. 2024;4(1) SCOPUS ID: 2-s2.0-85201215566 01/01/2024

• Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors' reply.

  (Singla S, Putman M, Liew J, Gordon K.) Lancet Rheumatol. 2023 Jun;5(6):e313 PMID: 38251598 01/22/2024

• Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.

  (Singla S, Putman M, Liew J, Gordon K.) Lancet Rheumatol. 2023 Apr;5(4):e200-e207 PMID: 38251522 01/22/2024

• Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review

  (Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, Felding J, Warren RB.) Dermatology and Therapy. December 2023;13(12):3031-3042 SCOPUS ID: 2-s2.0-85175655223 12/01/2023